Mergers & Acquisitions Mergers & Acquisitions

Comment: Big Tech, Big Pharma and China face new scrutiny as EU recasts merger rules

By Nicholas Hirst
  • 03 May 2021 10:17
  • 04 May 2021 04:19
The EU's oversight of takeovers and acquisitions is undergoing its biggest revolution since the bloc's merger review was introduced in 1989.

A plethora of new initiatives at the national and EU level will see certain dealmakers — Big Tech, Big Pharma and Chinese buyers — navigating a maze of checks and approvals.

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News